 | | Vol. 13.28 – 5 August, 2021 |
| |
|
|
| Scientists investigated if MSCs derived from the amniotic membrane could support the ex vivo expansion of hematopoietic stem cell and progenitor cells.
[Stem Cells Translational Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Using two different kinds of invasion assays, this study aimed at investigating and characterizing the 3D migratory capacity of human amniotic fluid stem cells, a well-established fetal stem cell type.
[Stem Cells] |
|
|
|
| The authors examined the effect human amniotic epithelial cells had on the liver progenitor cell response and hepatic oxidative stress in an experimental model of non-alcoholic steatohepatitis.
[Stem Cell Research & Therapy] |
|
|
|
| Investigators evaluated the clinical outcome of severe/critically severe 210 COVID-19 patients treated with umbilical cord-MSCs.
[Stem Cell Reviews and Reports] |
|
|
|
| Human umbilical cord MSC-derived exosomes carrying miR-378a-5p inhibited NLRP3 inflammasomes and abrogated cell pyroptosis to protect against dextran sulfate sodium-induced colitis.
[Stem Cell Research & Therapy] |
|
|
|
| Natural killer cells were isolated from human umbilical cord blood from a healthy newborn and reprogrammed by episomal vectors carrying reprograming factors L-MYC, LIN28, OCT4, SOX2, KLF4, EBNA-1, and shRNA against p53 delivered using nucleofection.
[Stem Cell Research] |
|
|
|
| A model of HTLV-1 and S. stercoralis coinfection in CD34+ umbilical cord blood hematopoietic stem cell engrafted humanized mice was established.
[PLOS Neglected Tropical Diseases] |
|
|
|
| Researchers evaluated intratracheal MSCs as an approach to treat an hyperoxia-induced bronchopulmonary dysplasia animal model and compared the therapeutic effects between amniotic fluid-, umbilical cord- and bone marrow-MSCs.
[Journal of Cellular and Molecular Medicine] |
|
| | | The authors present a critical analysis of the risks, limitations, challenges, and opportunities that place MSC-based products as a therapeutic strategy that may complement the current arsenal against COVID-19 and reduce the pandemic’s unmet medical needs.
[Stem Cell Research & Therapy] |
|
|
| | | Hope Biosciences Stem Cell Research Foundation has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived MSCs in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis.
[Hope Biosciences Stem Cell Research Foundation (BusinessWire, Inc.)] |
|
|
| | | October 28 – 29, 2021
Virtual |
|
|
| | | | | UCLA Jules Stein Eye Institute – Los Angeles, California, United States |
|
|
| | | University of Gothenburg – Gothenburg, Sweden |
|
|
| | | Princess Margaret Cancer Centre – Toronto, Ontario, United States |
|
|
| | | Mercer University – Savannah, Georgia, United States |
|
|
| | Dalhousie University – Halifax, Nova Scotia, Canada |
|
|
| |
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
